The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3.
 
Maen Abdelrahim
Consulting or Advisory Role - AstraZeneca; Ipsen
 
Gazala Khan
Honoraria - Helsinn Therapeutics/QED Therapeutics; Helsinn Therapeutics/QED Therapeutics; Incyte; Pfizer; QED Therapeutics
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - UCANCERVIVE
Travel, Accommodations, Expenses - Helsinn Therapeutics
 
Hassan Hatoum
Consulting or Advisory Role - Foundation Medicine
 
Alice Zervoudakis
No Relationships to Disclose
 
Farshid Dayyani
Consulting or Advisory Role - AstraZeneca; Eisai
Speakers' Bureau - Astellas Pharma; Exelixis; ipsen; SERVIER; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Li Zhang
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Jia Li
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Fiona Maxwell
Employment - Ipsen
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Mary Linton Peters
Stock and Other Ownership Interests - Abbott Laboratories (I); Abbott Laboratories (I); Agios; Amgen (I); Johnson & Johnson (I); Lilly; Lilly (I); Medtronic; Medtronic (I); Merck; Merck (I); Pfizer (I); Procter & Gamble
Research Funding - AstraZeneca (Inst); Bayer (Inst); Helsinn Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nucana (Inst)